Name of Division: Immunodermatology

Staff

Education

　　Undergraduate Course

　Medical students have both lectures and clinical practice, including for outpatients as well as bedside training with inpatients.

　　Graduate Course

　Freshmans will have a training for dermatology at University Hospital for the first year. They have inpatients with their senior doctors and learn the therapy, pathology, or technique of laboratory examinations. At the second year, they will be further trained at the blanch hospital.

Research Subjects

　　　Main research projects are;

　　・Allergic contact dermatitis

　In order to clarify whether Th2 type cytokines or mast cells play a role in the elicitation of contact hypersensitivity, Stat6 deficient mice were examined in the induction of CHS. Then we have recently demonstrated that both mast cells and Th2 cells are essential in the elicitation of CHS. Recently, our group is investigating a gene therapy for CHS by Decoy.

　　・Atopic dermatitis

　We have recently established a model mice for atopic dermatitis by the injection of anti-DNP antibody and challenge with DNFB. By using this model, we examined whether STAT6 is essential in the induction of late phase reaction. We have recently reported that STAT6 plays a major role in the induction of late phase reaction. Now, we are investigation the method of gene therapy for atopic dermatitis by using STAT6 Decoy.

　　・Eosinophils

　Blood eosinophilia and/or eosinophil infiltration into the skin is observed in several allergic skin diseases. Of primary interest to our laboratory are the mechanisms of eosinophil recruitment into the skin and pathogenic roles of eosinophils in skin diseases. To analyze these issues, we have established mouse and guinea pig models of eosinophilia. In addition, we are investigating the regulatory mechanisms of cell adhesion molecules on eosinophils and endothelial cells, biochemical properties of human eosinophil granule proteins, and eosinophil-specific chemoattractant produced by keratinocytes and fibroblasts.

　　・Scleroderma

　We have recently established a mouse model for scleroderma by repeated local injections of bleomycin (See publications). Induced skin changes mimicked that of human scleroderma both histologically and biochemically. The significance of this model is ・) Dermal sclerosis is certainly induced by a simple technique in a short period, ・) Analysis of early phase, which is prior to the onset of scleroderma, can be possible, ・) Therapeutic approach including gene therapy can be available. Our group is currently investigating the pathogenesis of cutaneous sclerosis as well as new therapies by using this model.

Publications (1999-2001)

1999

　 1. Takayama K, Yokozeki H, Ghoreishi M, Satoh T, Katayama I, Umeda T, Nishioka K: IL-4 inhibits the migration of human Langerhans cells through the downregulation of TNF receptor II expression. J Invest Dermatol 1999; 113: 541-546.

　 2. Yamazaki S, Katayama I, Kurumaji Y, Yokozeki H, Nishioka K: Treatment of reticular erythematous mucinosis with a large dose of ultraviolet B radiation and steroid impregnated tape. J Dermatol 1999; 26: 115-118.

　 3. Yamazaki S, Koyano T: A case of pediatric Behcet's disease with intestinal involvement. J Dermatol 1999; 26: 160-163.

　 4. Takagawa S, Nakamura S, Nishioka K: Radiation-induced erythema nodosum. Br J Dermatol 1999; 140: 372-373.

　 5. Takagawa S, Maruyama R, Yokozeki H, Nishioka K: Skin invasion of Hodgikin's disease mimicking scrofuloderma. J Dermatol 1999; 26: 268-270.

　 6. Satoh T, Takahashi Y, Yokozeki H, Katayama I, Nishioka K: Cutaneous angiosarcoma with thrombocytopenia. J Am Acad Dermatol 1999; 40: 872-876.

　 7. Sasaki G, Satoh T, Yokozeki H, Katayama I, Nishioka K: Confluent ecchymoses on the lower extremities of a malnourished patient. J Dermatol 1999; 26: 399-401.

　 8. Taniguchi H, Ohki O, Yokozeki H, Katayama I, Tanaka A, Kiyosawa M, Nishioka K: Cataract and retinal detachment in patients with severe atopic dermatitis who were withdrawn from the use of topical corticosteroid. J Dermatol 1999; 26: 658-665.

　 9. Yamamoto T, Yokoyama A: Lymphocyte response to superantigen in a patient with pityliasis rubra pilaris with a childhood onset. Int J Dermatol 38: 638-640, 1999.

　10. Yamamoto T, Katayama I, Nishioka K: Fibroblast proliferation by bleomycin-stimulated peripheral blood mononuclear cell factors. J Rheumatol 26: 609-615, 1999.

　11. Yamamoto T, Katayama I, Nishioka K: Peripheral blood mononuclear cells proliferative response to staphylococcal superantigen in patients with psoriasis arthropathy. Eur J Dermatol 9: 17-21, 1999.

　12. Yamamoto T, Yokoyama A: White, fibrous, papular lesions associated with systemic lupus erythematosus-Is this an ongoing scar following vascular involvement? Acta Derm Venereol (Stockh) 79: 240, 1999.

　13. Yamamoto T, Katayama I, Nishioka K: Increased serum level of stem cell factor in disease progression of hyperpigmented mycosis fungoides. Br J Dermatol 140: 765-766, 1999.

　14. Yamamoto T, Umeda T, Yokozeki H, Nishioka K: Expression of bFGF and its receptor in angiosarcoma. J Am Acad Dermatol 41: 127-129, 1999.

　15. Yamamoto T, Katayama I, Nishioka K: Nitrite production in mouse 3T3 fibroblasts by bleomycin-stimulated peripheral blood mononuclear cell factors. Clin Exp Rheumatol 17; 343-6, 1999.

　16. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K: Animal model of sclerotic skin. I: Local injections of bleomycin induce dermal sclerosis mimicking scleroderma. J Invest Dermatol 112: 456-462, 1999.

　17. Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K: Animal model of sclerotic skin. II: Bleomycin-induced scleroderma in genetically mast cell deficient WBB6F1-W/Wv mice. J Rheumatol 26; 2628-2634, 1999.

　18. Yamamoto T, Takagawa S, Katayama I, Nishioka K: Anti-sclerotic effect of antibody against TGF-β in bleomycin-induced dermal sclerosis in mice. Clin Immunol 92; 6-13, 1999.

　19. Yamamoto T, Takagawa S, Katayama I, Mizushima Y, Nishioka K: Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: Implications for the treatment of systemic sclerosis. J Invest Dermatol 113; 843-847, 1999.

2000

　 1. Yokozeki H, Ghoreishi K, Takagawa S, Takayama K, Satoh T, Katayama I, Takeda K, Akira S, Nishioka K: STAT 6 is essential in the induction of contact hypersensitivity. J Exp Med 2000; 191: 995-1004.

　 2. Yokozeki H: Drug eruptions on the elderly. Asian Med J 2000; 43: 453-458.

　 3. Satoh T, Yokozeki H, Nishioka K: Pathogenic roles of eosinophils in guinea-pig contact sensetivity: regulation of dermal eosinophilia with remotely administered IL-5. Clin Exp Immunol 2000; 122: 300-307.

　 4. Sasaki G, Satoh T, Yokozeki H, Katayama I, Nishioka K: Regulation of cyclophosphamide-induced eosinophilia in contact sensitivity: functional roles of interleukin-5-producing CD4 (+) lymphocytes. Cell Immunol 2000; 203: 124-133.

　 5. Ghoreishi M, Yokozeki H, Wu Ming Hua, Nishioka K: Expression of 27 KD, 65 KD and 72/73 KD heat shock protein in atopic dermatitis: Comparison with those in normal skin and contact dermatitis. J Dermatol 2000; 27: 370-379.

　 6. Ghoreishi M: Heat shock proteins in the pathogenesis of inflammatory skin diseases. J Med Dent Sci 2000; 47: 143-150.

　 7. Takagawa S, Satoh T, Yokozeki H, Nishioka K: Multiple minute digitate hyperkeratoses. Br J Dermatol 2000; 142: 1044-1046.

　 8. Imai K, Tatsumi H, Katayama Y: Mechanosensitive chloride channels on the growth cones of cultured rat dorsal root ganglion neurons. Neuroscience 2000; 97: 347-355.

　 9. Miyazaki Y, Yokozeki H, Sherif A, Igawa K, Minatohara K, Satoh T, Katayama I, Nishioka K: Glucocorticoid augmente the chemically induced production and gene expression of interleukin-1α through NF-kB and AP-1 activation on murine epidermal cells. J Invest Dermatol 2000; 115: 746-752.

　10. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T: Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1α loop. J Immunol 2000; 164: 6174-6179.

　11. Yamamoto T, Hartmann K, Eckes B, Krieg T: Mast cells enhance contraction of three-dimensional collagen lattices by fibroblasts by cell-cell interaction: role of stem cell factor/c-kit. Immunology 2000; 99: 435-439.

　12. Yamamoto T, Takagawa S, Kuroda M, Nishioka K: Effect of interferon-γ on experimental scleroderma induced by bleomycin. Arch Dermatol Res 2000; 292: 362-365.

　13. Yamamoto T, Kuroda M, Nishioka K: Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000; 292: 535-541.

　14. Yamamoto T, Eckes B, Krieg T: Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts. Arch Dermatol Res 2000; 292: 556-561.

　15. Yamamoto T, Katayama I, Nishioka K: A rare association of systemic sclerosis with psoriasis vulgaris. J Dermatol 2000; 27: 346-349.

　16. Yamamoto T, Nishioka K: Vitiligo vulgaris associated with hepatitis C virus. J Dermatol 2000; 27: 416-417.

　17. Yamamoto T, Matsuuchi M, Irimajiri J, Otoyama K, Nishioka K: Topical anthralin for psoriasis vulgaris: Evaluation of 70 Japanese patients. J Dermatol 2000; 27: 482-485.

　18. Yamamoto T, Yokoyama A: Eosinophil infiltration in the sclerodermoid cutaneous metastasis of a breast cancer. J Dermatol 2000; 27: 552-553.

　19. Yamamoto T, Otoyama K, Nishioka K: Unusual annular pustular psoriasis in a patient with type C hepatitis. J Dermatol 2000; 27: 802-803.

　20. Yamamoto T, Katayama I, Nishioka K: Possible contribution of stem cell factor in psoriasis vulgaris. J Dermatol Sci 2000; 24: 171-176.

　21. Yamamoto T, Umeda T, Nishioka K: Immunohistological distribution of stem cell factor and kit receptor in angiosarcoma. Acta Derm Venereol 2000; 80: 443-445.

　22. Yamamoto T, Nishioka K: Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 2000; 80: 451.

　23. Yoshida T, Higuchi T, Hagiyama H, Strasser A, Nishioka K, Tsubata T: Rapid B cell apoptosis induced by antigen receptor ligation does not require Fas (CD95/APO-1), the adaptor protein FADD/MORT1 or CrmA-sensitive caspases but is defective in both MRL-+/+ and MRL-lpr/lpr mice. Int Immunol 2000; 12: 517-526.

　

[Graduate School, School of Medicine]

［TOKYO MEDICAL AND DENTAL UNIVERSITY］